Q-omics provides the consensus-scored ATP8B4 profile across patient tissues and cancer cell-line models. ATP8B4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ATP8B4 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, ATP8B4 RNA expression shows 22,230 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, BLCA, and GBM as cancer lineages where ATP8B4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP8B4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP8B4 survival associations across molecular data types. ATP8B4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP8B4 RNA expression–survival associations across cancer types. High ATP8B4 expression shows unfavorable associations in LGG and DLBC, but favorable associations in SKCM, HNSC, LUAD and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ATP8B4 RNA expression.
This table summarizes ATP8B4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ATP8B4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP8B4 shows lower tumor expression in BLCA, COAD, UCEC, THCA and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher ATP8B4 RNA expression in normal versus tumor tissue (log2 FC = −0.737, t-test p < 0.001).
This table shows molecular features associated with ATP8B4 in patient tissues and cancer cell lines. In patient samples, ATP8B4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP8B4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
